EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Clinical Trials Related to Neuroendocrine Tumors
Related studies linked through entity extraction aliases.
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis
- Status
- COMPLETED
- Phase
- N/A
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- NA
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE3
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE3
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- N/A
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)
- Status
- COMPLETED
- Phase
- NA
5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor'
- Status
- COMPLETED
- Phase
- N/A
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
- Status
- COMPLETED
- Phase
- PHASE2
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
- Status
- UNKNOWN
- Phase
- PHASE2
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours
- Status
- COMPLETED
- Phase
- PHASE2
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
- Status
- TERMINATED
- Phase
- PHASE1